Further Insights into the Measurement of Free Polysaccharide in Meningococcal Conjugate Vaccines

被引:1
作者
Beresford, Nicola J. [1 ]
De Benedetto, Gianluigi [1 ]
Lockyer, Kay [1 ]
Gao, Fang [1 ]
Burkin, Karena [1 ]
Lalwani, Karan [1 ]
Bolgiano, Barbara [1 ]
机构
[1] Med & Healthcare Prod Regulatory Agcy, Sci Res & Innovat Div, South Mimms EN6 3QG, England
关键词
CRM; filtration; glycoconjugate; HPAEC; HPLC; meningitis; meningococcal; Neisseria meningitidis; stability; ANION-EXCHANGE CHROMATOGRAPHY; INFLUENZAE TYPE-B; ULTRAFILTRATION BEHAVIOR; PNEUMOCOCCAL POLYSACCHARIDES; CAPSULAR POLYSACCHARIDES; GLYCOCONJUGATE VACCINES; DIPHTHERIA-TOXIN; SACCHARIDE; STABILITY; SEROGROUP;
D O I
10.3390/vaccines13020167
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The purpose of this study was to further characterize the ultrafiltration (UF) method for determining free saccharide levels in glycoconjugate vaccines and compare it with other methods used for the determination of free saccharide levels in meningococcal glycoconjugate vaccines. Methods: We performed experiments on both meningococcal glycoconjugates and capsular polysaccharides, and compared UF, deoxycholate (DOC) precipitation, and solid-phase extraction (SPE) methods. Meningococcal capsular polysaccharides from groups A (MenA), C (MenC), and W (MenW) were depolymerized and characterized using SEC-MALS (size-exclusion chromatography with multi-angle laser light scattering) to determine the molecular weight and hydrodynamic size and then subjected to UF. The free saccharide content was quantified using HPAEC-PAD (high-performance anion-exchange chromatography with pulsed amperometric detection). Results: The characterization of size-reduced group C polysaccharide revealed weight-average molecular mass (Mw) ranging from 22,200 g/mol to 287,300 g/mol and hydrodynamic radii of 3.7 to 19.5 nm. Pore size studies confirmed that polysaccharides with diameters up to 15 nm filtered through the 100 kDa cellulose membrane. The smallest PS fragment tested (22,200 g/mol, 7.4 nm diameter) was partially recovered from the 30 kDa membrane. For MenC-CRM197, DOC yielded the lowest free saccharide content (<1%), UF gave moderate results (7-8%), and SPE showed the highest and most variable values (up to 15%). For MenA- and MenW-CRM197, UF and DOC consistently provided low free saccharide levels (<2% and 3-11%, respectively). Conclusions: The upper limits on the size of free group C meningococcal polysaccharides that can be ultrafiltered were assessed. Differences in the relative amount of free saccharide were observed between various methods used to control meningococcal conjugate vaccines.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis
    Conti, Andrea
    Broglia, Gaia
    Sacchi, Chiara
    Risi, Fabrizia
    Barone-Adesi, Francesco
    Panella, Massimiliano
    [J]. VACCINES, 2023, 11 (01)
  • [32] Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration
    Gasparini, Roberto
    Tregnaghi, Miguel
    Keshavan, Pavitra
    Ypma, Ellen
    Han, Linda
    Smolenov, Igor
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (01) : 81 - 93
  • [33] Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines
    Hargreaves, James R.
    Greenwood, Brian
    Clift, Charles
    Goel, Akshay
    Roemer-Mahler, Anne
    Smith, Richard
    Heymann, David L.
    [J]. LANCET, 2011, 378 (9806) : 1885 - 1893
  • [34] Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines
    Pollard, Andrew J.
    Perrett, Kirsten P.
    Beverley, Peter C.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2009, 9 (03) : 212 - 220
  • [35] Analytical technology development to monitor the stability of Polysaccharide-Protein conjugate vaccines
    Smith, William J.
    Ahl, Patrick L.
    Wang, Bei
    Hamm, Melissa
    Rustandi, Richard R.
    Winters, Michael A.
    Blue, Jeffrey T.
    [J]. VACCINE, 2022, 40 (31) : 4182 - 4189
  • [36] Memory immune response generated in Cercopithecusaethiops against meningococcal polysaccharide serogroup C conjugate vaccine
    Carmenate, T
    Guirola, M
    Alvarez, A
    Canaán, L
    González, S
    Caballero, E
    Menéndez, T
    Guillén, G
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2005, 43 (02): : 133 - 140
  • [37] PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine
    Huang, Qingrui
    Li, Dongxia
    Kang, Aijun
    An, Wenqi
    Fan, Bei
    Ma, Xiaowei
    Ma, Guanghui
    Su, Zhiguo
    Hu, Tao
    [J]. JOURNAL OF CONTROLLED RELEASE, 2013, 172 (01) : 382 - 389
  • [38] Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine
    El Bashir, H
    Heath, PT
    Papa, T
    Ruggeberg, JU
    Johnson, N
    Sinha, R
    Balfour, G
    Booy, R
    [J]. VACCINE, 2006, 24 (14) : 2544 - 2549
  • [39] Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile
    Villena, R.
    Valenzuela, M. T.
    Bastias, M.
    Santolaya, M. E.
    [J]. VACCINE, 2019, 37 (46) : 6915 - 6921
  • [40] Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine
    Khalil, Mohamed
    Al-Mazrou, Yagob
    Findlow, Helen
    Chadha, Helen
    Castells, Valerie Bosch
    Oster, Philipp
    Borrow, Ray
    [J]. VACCINE, 2014, 32 (43) : 5715 - 5721